Acrobiosystems Co

Acrobiosystems Co Shares Outstanding

The The number of shares of Acrobiosystems Co (301080.SZ) as of Nov 11, 2026 is 167.18 M. In the previous year, The number of shares was 167.18 M — a change of 0.00% (lower).

Shares Outstanding

167.18 M

YoY

0.00%

Last updated:

In 2025, Acrobiosystems Co had 167.18 M outstanding stocks, a 0.00% change from the 167.18 M stocks in the previous year.

The Acrobiosystems Co Shares Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Shares Outstanding
Date
Shares Outstanding
Jan 1, 2020
167.18 M CNY
Jan 1, 2021
167.18 M CNY
Jan 1, 2022
167.18 M CNY
Jan 1, 2023
167.18 M CNY
Jan 1, 2024
167.18 M CNY
Jan 1, 2025
167.18 M CNY
Jan 1, 2026 (e)
168.00 CNY
Jan 1, 2027 (e)
168.00 CNY
The Acrobiosystems Co Shares Outstanding history
YEARShares OutstandingYoY
est168.000.00%
est168.00-100.00%
167.18 M0.00%
167.18 M0.00%
167.18 M0.00%
167.18 M0.00%
167.18 M0.00%
167.18 M0.00%
167.18 M0.00%
167.18 M—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Number of shares

Acrobiosystems Co shares outstanding

The number of shares of Acrobiosystems Co was 168 M in 2025. This indicates how many shares Acrobiosystems Co is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
168.00 M Stocks
Jan 1, 2021
168.00 M Stocks
Jan 1, 2022
80.00 M Stocks
Jan 1, 2023
120.00 M Stocks
Jan 1, 2024
168.00 M Stocks
Jan 1, 2025
168.00 M Stocks
Jan 1, 2026 (e)
168.00 M Stocks
Jan 1, 2027 (e)
168.00 M Stocks

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Shares Outstanding Details

Evaluating Acrobiosystems Co's Shares Outstanding

Acrobiosystems Co's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Acrobiosystems Co’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Acrobiosystems Co’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Acrobiosystems Co’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Acrobiosystems Co stock

The number of shares of Acrobiosystems Co is 167.18 M in 2025.

The number of shares of Acrobiosystems Co changed from 167.18 M to 167.18 M, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The number of shares Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

The number of shares indicates the total number of a company's shares. This includes not only the shares available on the market, but also the shares held by shareholders and the shares retained by the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co